Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CCR9 | P51686 | 2/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.31 |
| ▸ | RORB | Q92753 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4953414 | 0.84 | HSD11B1 (0.38) | HSD11B1HSD17B3MEN1KMT2AMAPT | |
| SCHEMBL12395299 | 0.83 | ALDH1A1 (0.35) | HSD11B1HSD17B3MAPT | |
| SCHEMBL2157076 | 0.77 | HSD11B1 (0.33) | HSD11B1HSD17B3IKBKB | |
| SCHEMBL2156009 | 0.69 | L3MBTL1 (0.35) | — | |
| SCHEMBL2156569 | 0.63 | ALDH1A1 (0.33) | MEN1KMT2AMAPT | |
| SCHEMBL2155601 | 0.63 | — | — | |
| SCHEMBL8394618 | 0.63 | ALDH1A1 (0.52) | HSD11B1HSD17B3MEN1KMT2AMAPT | |
| SCHEMBL2155692 | 0.62 | HSD11B1 (0.33) | HSD11B1HSD17B3MEN1KMT2AMAPT | |
| SCHEMBL8394817 | 0.61 | MITF (0.47) | HSD11B1HSD17B3MEN1KMT2AMAPT | |
| SCHEMBL12832706 | 0.60 | ALDH1A1 (0.48) | HSD11B1HSD17B3MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973072-B2 | Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example | GRUENENTHAL GMBH (DE) | 2011-07-05 | — | — | US | claimed |
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | GRUENENTHAL GMBH (DE) | 2008-07-03 | — | — | US | claimed |
| EP-1888555-A2 | SUBSTITUTED BENZO-CONDENSED CYCLOHEXANONE DERIVATIVES AND THE USE THEREOF FOR MEDICAMENT PRODUCTION | Grünenthal GmbH (DE) | 2008-02-20 | — | — | EP | claimed |
| WO-2006122771-A2 | SUBSTITUTED BENZO-CONDENSED CYCLOHEXANONE DERIVATIVES AND THE USE THEREOF FOR MEDICAMENT PRODUCTION | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | claimed |
| US-7973072-B2 | Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example | GRUENENTHAL GMBH (DE) | 2011-07-05 | — | — | US | disclosed |
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | GRUENENTHAL GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | BCKDK, SYMPK, DHPS | HSD11B1 716/4885HSD17B3 305/4885APEX1 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.